Who We Are

ACF_logo _smallThe goal of the Anticancer Fund is to expand cancer treatment options by supporting clinical trials with repurposed drugs and other interventions with no or low commercial value for the pharmaceutical industry.
Pan Pantziarkapan Pan has been working with the Anticancer Fund since December 2013 and is coordinating the ReDO-project in collaboration with Gauthier. Pan is the founder of the George Pantziarka TP53 Trust, a UK-based charity that supports families afflicted with Li Fraumeni Syndrome, a rare genetic condition that pre-disposes sufferers to cancer. Although he has a PhD in computer science, he has also published in oncology and is engaged in research on Li Fraumeni Syndrome in addition to his work with ReDO.
Gauthier BoucheGauthier Gauthier is the medical director of the Anticancer Fund. Gauthier holds an MD and a Master’s of Public Health. His interest in drug repurposing came after reading several articles reporting striking results in cancer patients with repurposed drugs. Gauthier is managing the ReDO project for the Anticancer Fund.
Lydie is the Managing Director of the Anticancer Fund. She holds a PhD in Protein Biochemistry and acted as VP R&D in the biopharmaceutical industry. Lydie supervises the work done by Gauthier and Pan for the ReDO project.
gc_logoGlobalCures is a non-profit medical research organization dedicated to curing patients with cancer and other diseases by rapidly promoting clinical research on scientifically promising, readily available and cost-effective treatments. Our strategy is to repurpose existing drugs, currently being overlooked for cancer use, due to lack of profitability.
Vidula Sukhatmevidula Vidula is co-founder and Chief Executive Officer of GlobalCures. She holds an MS in mathematics from Northeastern University and an MS from the Harvard School of Public Health in epidemiology. She has 20 years of experience in information systems in a healthcare environment.
Vikas Sukhatmevikas Vikas received a PhD in physics from MIT and an MD from Harvard Medical School. He is a physician engaged in both basic science and patient-oriented research at Harvard, where he is the Victor J. Aresty Professor of Medicine. He is also the Chief Academic Officer at Beth Israel Deaconess Medical Center, Boston. His primary interest is in cancer research but his research has spanned such diverse areas as toxemia of pregnancy and sepsis.